Nov. 10 (Bloomberg) -- AstraZeneca Plc’s Faslodex breast-cancer drug failed to win backing from the U.K.’s health-cost regulator in final guidelines on treating the disease.
Britain’s National Health Service shouldn’t use the drug, also known as fulvestrant, as an alternative to a class of drugs known as aromatase inhibitors, the National Institute for Health and Clinical Excellence, known as NICE, said today in an e-mailed statement. The agency, which advises the NHS on cost-effectiveness, said in a preliminary decision in August that tests didn’t show conclusively that the treatment is more effective than current offerings.
Faslodex was approved for sale in the European Union in 2004 for the treatment of post-menopausal women whose cancer had advanced following anti-estrogen therapy. The drug generated sales of $345 million in 2010, according to Bloomberg data.
To contact the reporter on this story: Kristen Hallam in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org